Biotech · Private company
Cyllene Therapeutics
Track this companyFree. Adds Cyllene Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- EG110APhase 2 · Neurogenic Detrusor OveractivityClinicalTrials.gov · fetched Nov 12, 2026
- EG110APhase 2 · Urinary Bladder, OveractiveClinicalTrials.gov · fetched Nov 12, 2026
- Patient-reported OutcomePhase 2 · Urinary Bladder, OveractiveClinicalTrials.gov · fetched Nov 12, 2026
- UrodynamicsPhase 2 · Urinary Bladder, OveractiveClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene TherapyPHASE1_PHASE2 · NOT_YET_RECRUITING · started Apr 1, 2026ClinicalTrials.gov NCT07227285 · fetched Nov 12, 2026
- Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent CatheterizationPHASE1_PHASE2 · RECRUITING · started Jan 8, 2025ClinicalTrials.gov NCT06596291 · fetched Nov 12, 2026